Key Market Indicator:
F&G: 23
25.437,00 NASDAQ · 47.724,00 DOW · 6.846,55 S&P · 4.219,18 Gold · 62,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
DE000A3MQR65
Filter zurücksetzen
© EQS Newswire
28.11.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG and HELLMUT RUCK GmbH have concluded an exclusive distribution agreement for plasma devices
Article
News Preview
Viromed Medical AG and HELLMUT RUCK GmbH have concluded an exclusive distribution agreement for plasma devices Rellingen, November 28, 2025 – Viromed Medical AG, a specialist in medical technologies, and HELLMUT RUCK GmbH, a leading provider of podiatry, foot care, and cosmetic solutions, announce the conclusion of an exclusive partnership for Eur......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.11.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed bestätigt Gespräche mit internationalem MedTech-Konzern hinsichtlich Kooperation im Bereich der Wundbehandlung
Article
News Preview
AD-HOC-MITTEILUNG Viromed bestätigt Gespräche mit internationalem MedTech-Konzern hinsichtlich Kooperation im Bereich der Wundbehandlung Pinneberg, 26. November 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), bestätigt Marktgerüchte, wonach sich die Gesellschaft in fortgeschrittenen Gesprächen mit einem weltweit agierenden MedTech-......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.11.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care
Article
News Preview
AD HOC ANNOUNCEMENTViromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care Pinneberg, November 26, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), confirms market rumors that the company is in advanced talks with a global MedTech company in the field of wound treatment about signin......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
21.10.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Reallocation of Viromed shares broadens investor base
Article
News Preview
Viromed Medical AG: Reallocation of Viromed shares broadens investor base Rellingen, October 21, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, Viromed is expanding its shareholder base by initiating the reallocation of Viromed shares held by the CEO and founder Uwe Pe......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
21.10.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Umplatzierungen von Viromed-Aktien erweitern Investorenbasis
Article
News Preview
Viromed Medical AG: Umplatzierungen von Viromed-Aktien erweitern Investorenbasis Rellingen, 21. Oktober 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, erweitert durch die begonnene Umplatzierung von Viromed-Aktien aus dem Besitz des Vorstands und Gründers Uwe Per......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.10.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships
Article
News Preview
PRESS RELEASE Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships Rellingen, October 01, 2025 – Viromed Medical Group ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has published its 2025 half-year report, which includes ......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.10.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG treibt Markteinführung neuer Produkte im ersten Halbjahr 2025 voran und baut strategische Partnerschaften aus
Article
News Preview
PRESSEMITTEILUNG Viromed Medical AG treibt Markteinführung neuer Produkte im ersten Halbjahr 2025 voran und baut strategische Partnerschaften aus Rellingen, 1. Oktober 2025 – Die Viromed Medical Gruppe („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, hat ihren Halbjahresbericht 2025 veröffentli......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG launches in vivo and ex vivo study with cold plasma on living lungs
Article
News Preview
PRESS RELEASE Viromed Medical AG launches in vivo and ex vivo study with cold plasma on living lungs Rellingen, September 30, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, announces the start of a comprehensive in vivo and ex vivo study on living lungs. The in vivo a......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG startet In-vivo- und Ex-vivo-Studie mit Kaltplasma an lebenden Lungen
Article
News Preview
PRESSEMITTEILUNG Viromed Medical AG startet In-vivo- und Ex-vivo-Studie mit Kaltplasma an lebenden Lungen Rellingen, 30. September 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, gibt den Start einer umfangreichen In-vivo- und Ex-vivo-Studie an lebenden Lungen bek......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG startet Zulassungprozess für PulmoPlas® beim BfArM
Article
News Preview
PRESSEMITTEILUNG Viromed Medical AG startet Zulassungprozess für PulmoPlas® beim BfArM Rellingen, 23. September 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, hat den offiziellen Zulassungsprozess für ihr neues Produkt PulmoPlas® beim Bundesinstitut für Arzneimit......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG initiates approval process for PulmoPlas® with the Federal Institute for Drugs and Medical Devices (BfArM)
Article
News Preview
PRESS RELEASE Viromed Medical AG initiates approval process for PulmoPlas® with the Federal Institute for Drugs and Medical Devices (BfArM) Rellingen, September 23, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has initiated the official approval process for its new ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG initiates approval process for PulmoPlas(R) with the Federal Institute for Drugs and Medical Devices (BfArM)
Article
News Preview
RELLINGEN, DE / ACCESS Newswire / September 23, 2025 / Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has initiated the official approval process for its new product PulmoPlas® with the Federal Institute for Drugs and Medical Devices („Bundesinstitut für Ar...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
18.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Successful ISO 13485 certification paves the way for market launch of ViroCAP® in October 2025
Article
News Preview
Viromed Medical AG: Successful ISO 13485 certification paves the way for market launch of ViroCAP® in October 2025 Rellingen, September 18, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has received the ISO 13485 certification. This officially makes Viromed a medical ......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.09.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Erfolgreiche ISO-13485-Zertifizierung ebnet Weg für Markteinführung von ViroCAP® im Oktober 2025
Article
News Preview
Viromed Medical AG: Erfolgreiche ISO-13485-Zertifizierung ebnet Weg für Markteinführung von ViroCAP® im Oktober 2025 Rellingen, 18. September 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, hat die ISO-13485-Zertifizierung erhalten. Damit ist Viromed offiziell ein......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.07.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Hauptversammlung stimmt allen Beschlussvorlagen mit großer Mehrheit zu
Article
News Preview
Viromed Medical AG: Hauptversammlung stimmt allen Beschlussvorlagen mit großer Mehrheit zu Pinneberg, 29. Juli 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, hat heute ihre ordentliche virtuelle Hauptversammlung erfolgreich durchgeführt. Die Aktionärinnen und Akti......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.07.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Annual General Meeting approves all proposed resolutions by a large majority
Article
News Preview
Viromed Medical AG: Annual General Meeting approves all proposed resolutions by a large majority Pinneberg, 29. July 2025 – Viromed Medical AG (Viromed; ISIN: DE000A3MQR65), a medical technology company and a pioneer in cold plasma technology, today successfully held its Annual General Meeting in virtual form. The shareholders approved all resolut......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.07.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG enters into a distribution partnership with TriPart for the market launch of ViroCAP® and PulmoPlas® in Turkey
Article
News Preview
Viromed Medical AG enters into a distribution partnership with TriPart for the market launch of ViroCAP® and PulmoPlas® in Turkey Pinneberg, 24 July 2025 – Viromed Medical AG (Viromed; ISIN: DE000A3MQR65), a medical technology company and a pioneer in cold plasma technology, has entered into a new distribution partnership with TriPart TITAN GmbH &......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.07.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG vereinbart Vertriebskooperation mit TriPart für die Markteinführung von ViroCAP® und PulmoPlas® in der Türkei
Article
News Preview
Viromed Medical AG vereinbart Vertriebskooperation mit TriPart für die Markteinführung von ViroCAP® und PulmoPlas® in der Türkei Pinneberg, 24. Juli 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, hat eine neue Vertriebskooperation mit TriPart TITAN GmbH & Co. ......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.06.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026
Article
News Preview
Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026 Pinneberg, June 30, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, expects dynamic sales growth in the coming financial years. In detail, revenue is expected to rise from EUR 1.37 milli......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.06.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG erwartet dynamisches Wachstum und veröffentlicht Prognose für 2025 und 2026
Article
News Preview
Viromed Medical AG erwartet dynamisches Wachstum und veröffentlicht Prognose für 2025 und 2026  Pinneberg, 30. Juni 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, erwartet für die kommenden Geschäftsjahre ein dynamisches Umsatzwachstum. Konkret soll der Umsatz na......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.06.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Cold plasma technology shows potential to significantly reduce deaths in ventilated patients
Article
News Preview
Viromed Medical AG: Cold plasma technology shows potential to significantly reduce deaths in ventilated patients Pinneberg, June 23, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has been informed by the Hannover Medical School (“Medizinische Hochschule Hannover“; MHH......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.06.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Kaltplasma-Technologie zeigt Potenzial zur signifikanten Reduktion von Todesfällen bei beatmeten Patienten
Article
News Preview
Viromed Medical AG: Kaltplasma-Technologie zeigt Potenzial zur signifikanten Reduktion von Todesfällen bei beatmeten Patienten Pinneberg, 23. Juni 2025 – Die Viromed Medical AG („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, ist von der Medizinischen Hochschule Hannover (MHH) über weitere Detai......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.06.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG plant Änderung im Aufsichtsrat und Aufsichtsratsvorsitz
Article
News Preview
Viromed Medical AG plant Änderung im Aufsichtsrat und Aufsichtsratsvorsitz  Pinneberg, 06. Juni 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, schlägt der ordentlichen Hauptversammlung am 29. Juli 2025 vor, Herrn Dr. Thomas Gutschlag neu in den Aufsi......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.06.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG plans change in the Supervisory Board and Chairman of the Supervisory Board
Article
News Preview
Viromed Medical AG plans change in the Supervisory Board and Chairman of the Supervisory Board  Pinneberg, June 06, 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer in cold plasma technology, proposes to the Annual General Meeting on July 29, 2025 that Dr. Thomas Gutschlag be elected......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Revolutionäre Kaltplasmatherapie für VAP (ventilatorassoziierte Pneumonie) zeigt 100% Wirksamkeit in einer in vitro-Studie mit MRSA und humanen Lungenzellen (Alveolen)
Article
News Preview
Viromed Medical AG: Revolutionäre Kaltplasmatherapie für VAP (ventilatorassoziierte Pneumonie) zeigt 100% Wirksamkeit in einer in vitro-Studie mit MRSA und humanen Lungenzellen (Alveolen) Studie bestätigt die Wirksamkeit und Sicherheit einer Kaltplasmatherapie Pinneberg, 14. Mai 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Revolutionary cold plasma therapy for the treatment of ventilator-associated pneumonia (VAP) shows 100% efficacy in an in vitro study with MRSA and human lung cells (alveoli)
Article
News Preview
Viromed Medical AG: Revolutionary cold plasma therapy for the treatment of ventilator-associated pneumonia (VAP) shows 100% efficacy in an in vitro study with MRSA and human lung cells (alveoli) Study confirms the effectiveness and safety of cold plasma therapy Pinneberg, May 14, 2025 - Viromed Medical AG ("Viromed", FSE: VMED; ISIN: DE000A3MQR65)......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Kaltplasmatherapie für VAP (ventilatorassoziierte Pneumonie) zeigt 100% Wirksamkeit in einer in vitro-Studie mit MRSA und humanen Lungenzellen (Alveolen)
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014Viromed Medical AG: Kaltplasmatherapie für VAP (ventilatorassoziierte Pneumonie) zeigt 100% Wirksamkeit in einer in vitro-Studie mit MRSA und humanen Lungenzellen (Alveolen)Pinneberg, 14. Mai 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Exklusiver Vertrag für ViroCAP® My Plasma mit Landsberg First Class Aesthetic eröffnet Viromed Eintritt in den europäischen Kosmetikmarkt
Article
News Preview
Exklusiver Vertrag für ViroCAP® My Plasma mit Landsberg First Class Aesthetic eröffnet Viromed Eintritt in den europäischen Kosmetikmarkt  Pinneberg, 25. April 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, und Landsberg First Class Aesthetic  („Land......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Exclusive contract for ViroCAP® My Plasma with Landsberg First Class Aesthetic opens up Viromed's entry into the European cosmetics market
Article
News Preview
Exclusive contract for ViroCAP® My Plasma with Landsberg First Class Aesthetic opens up Viromed's entry into the European cosmetics market  Pinneberg, April 25, 2025 - Viromed Medical AG ("Viromed", Ticker: VMED; ISIN: DE000A3MQR65), a medical device company and pioneer in cold plasma technology, and Landsberg First Class Aesthetic ("Landsberg"), ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Exklusiver Vertrag für ViroCAP® My Plasma mit Landsberg First Class Aesthetic eröffnet Viromed Eintritt in den europäischen Kosmetikmarkt
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014  Exklusiver Vertrag für ViroCAP® My Plasma mit Landsberg First Class Aesthetic eröffnet Viromed Eintritt in den europäischen Kosmetikmarkt  Pinneberg, 25. April 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65) und Landsberg First ......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG welcomes Dr. Thomas Gutschlag as new Investor
Article
News Preview
Viromed Medical AG welcomes Dr. Thomas Gutschlag as new Investor  Pinneberg, April 23, 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in wound healing, intensive care medicine and air disinfection, has gained Dr. Thomas Gutschlag, founder ......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG gewinnt Dr. Thomas Gutschlag als neuen Investor
Article
News Preview
Viromed Medical AG gewinnt Dr. Thomas Gutschlag als neuen Investor   Pinneberg, 23. April 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie für Anwendungen in den Bereichen Wundheilung, Intensivmedizin und Raumluftentkeimung, hat Dr. Thomas Gutschlag, Gr......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Exklusive Vertriebspartnerschaft mit AMAMUS Vet für das Kaltplasma-Medizinprodukt ViroCAP® VET zum Einsatz in der Tiermedizin
Article
News Preview
Viromed Medical AG: Exklusive Vertriebspartnerschaft mit AMAMUS Vet für das Kaltplasma-Medizinprodukt ViroCAP® VET zum Einsatz in der Tiermedizin  Pinneberg, 10. April 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie für Anwendungen in den Bereichen Wun......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP® VET for veterinary use
Article
News Preview
Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP® VET for veterinary use  Pinneberg, April 10. April 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in wound healing, intensiv......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Exklusive Vertriebspartnerschaft mit AMAMUS Vet für das Kaltplasma-Medizinprodukt ViroCAP® VET zum Einsatz in der Tiermedizin
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014  Viromed Medical AG: Exklusive Vertriebspartnerschaft mit AMAMUS Vet für das Kaltplasma-Medizinprodukt ViroCAP® VET zum Einsatz in der Tiermedizin  Pinneberg, 10. April 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizin......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Einladung zum virtuellen Medical Roundtable zum Abschluss der Vertriebsvereinbarung mit der asiatischen UMECO Group am Mittwoch, dem 3. April 2025, 13:00 Uhr MESZ
Article
News Preview
Viromed Medical AG: Einladung zum virtuellen Medical Roundtable zum Abschluss der Vertriebsvereinbarung mit der asiatischen UMECO Group am Mittwoch, dem 3. April 2025, 13:00 Uhr MESZ  Pinneberg, 02. April 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
UMECO Group acquires exclusive marketing rights in Asia for cold plasma medical devices ViroCAP® and PulmoPlas®  
Article
News Preview
Viromed Medical AG: UMECO Group acquires exclusive marketing rights in Asia for cold plasma medical devices ViroCAP® and PulmoPlas®   Pinneberg, 01. April 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in air disinfection, wound healing an......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
UMECO Group erwirbt exklusive Vermarktungsrechte für Kaltplasma-Medizinprodukte ViroCAP® und PulmoPlas® im asiatischen Raum
Article
News Preview
Viromed Medical AG: UMECO Group erwirbt exklusive Vermarktungsrechte für Kaltplasma-Medizinprodukte ViroCAP® und PulmoPlas® im asiatischen Raum Pinneberg, 01. April 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie für Anwendungen im Bereich der Raumluf......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
UMECO Group erwirbt exklusive Vermarktungsrechte für Kaltplasma-Medizinprodukte ViroCAP® und PulmoPlas® im asiatischen Raum
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 Viromed Medical AG: UMECO Group erwirbt exklusive Vermarktungsrechte für Kaltplasma-Medizinprodukte ViroCAP® und PulmoPlas® im asiatischen Raum Pinneberg, 01. April 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizintec......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.04.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG: UMECO Group Acquires Exclusive Marketing Rights in Asia for Cold Plasma Medical Devices ViroCAP(R) and PulmoPlas(R)  
Article
News Preview
PINNEBERG, DE / ACCESS Newswire / April 1, 2025 / Viromed Medical AG ("Viromed", ticker:VMED; ISIN:DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in air disinfection, wound healing and intensive care medicine, has today signed an exclusive distribution agreement worth a total of EUR 152....
Themefolio
Profiler
Peergroup
© EQS Newswire
14.03.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG gibt vielversprechende Ergebnisse ihrer Studie zur Behandlung der ventilatorassoziierten Pneumonie (VAP) mit PulmoPlas® bei Intensivpatienten bekannt
Article
News Preview
Viromed Medical AG gibt vielversprechende Ergebnisse ihrer Studie zur Behandlung der ventilatorassoziierten Pneumonie (VAP) mit PulmoPlas® bei Intensivpatienten bekannt Pinneberg, 14. März 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie für Anwendungen......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.03.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG reports promising study results for PulmoPlas® in intensive care unit ventilator-associated pneumonia patients
Article
News Preview
Viromed Medical AG reports promising study results for PulmoPlas® in intensive care unit ventilator-associated pneumonia patients Pinneberg, Germany, March 14, 2025 - Viromed Medical AG (“Viromed”, Ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in room air sterilization, woun......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.03.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG gibt vielversprechende Ergebnisse ihrer Studie zur Behandlung der ventilatorassoziierten Pneumonie (VAP) mit PulmoPlas® bei Intensivpatienten bekannt
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 Viromed Medical AG gibt vielversprechende Ergebnisse ihrer Studie zur Behandlung der ventilatorassoziierten Pneumonie (VAP) mit PulmoPlas® bei Intensivpatienten bekannt Pinneberg, 14. März 2025 – Die Viromed Medical AG („Viromed“, Ticker: VMED; ISIN: DE000A......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.03.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG Reports Promising Study Results for PulmoPlas(R) in Intensive Care Unit Ventilator-Associated Pneumonia Patients
Article
News Preview
PINNEBERG, GERMANY / ACCESS Newswire / March 14, 2025 / Viromed Medical AG ("Viromed", Ticker:VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in room air sterilization, wound healing, and intensive care medicine, today announces promising study results for treating ventilator-...
Themefolio
Profiler
Peergroup
© EQS Newswire
07.03.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Strategic healthcare investor acquires further shares in private placement
Article
News Preview
Viromed Medical AG: Strategic healthcare investor acquires further shares in private placement Pinneberg, 7 March 2025 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has been informed by its majority shareholder (together with his wife) and CEO Uwe Perbandt about a further off-market placement of a total of 900,000 shares from his holdings......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.03.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Strategischer Investor aus der Gesundheitsbranche erwirbt weitere Aktien im Rahmen einer Umplatzierung
Article
News Preview
Viromed Medical AG: Strategischer Investor aus der Gesundheitsbranche erwirbt weitere Aktien im Rahmen einer Umplatzierung Pinneberg, 7. März 2025 – Die Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) wurde von ihrem Mehrheitsaktionär (gemeinsam mit seiner Frau) und Vorstand Uwe Perbandt über eine weitere außerbörsliche Umplatzierung von insg......
Themefolio
Profiler
Peergroup
© BusinessWire
28.02.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG reaches milestone for cooperation with multinational corporation
Article
News Preview
Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold...
Themefolio
Profiler
Peergroup
© EQS Newswire
28.02.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG erreicht Meilenstein für Kooperation mit weltweit tätigem Großkonzern
Article
News Preview
Viromed Medical AG erreicht Meilenstein für Kooperation mit weltweit tätigem Großkonzern Pinneberg, 28. Februar 2025 – Die Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) hat im Rahmen der am 11. Dezember 2024 per Ad-hoc-Mitteilung angekündigten umfangreichen Kooperation mit einem weltweit tätigen Großkonzern einen Meilenstein erreicht. Gegen......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.02.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG reaches milestone for cooperation with multinational corporation
Article
News Preview
Viromed Medical AG reaches milestone for cooperation with multinational corporation Pinneberg, 28 February 2025 –Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.02.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Successful placement of shares with a strategic investor in the healthcare industry to accelerate market entry in Europe
Article
News Preview
Viromed Medical AG: Successful placement of shares with a strategic investor in the healthcare industry to accelerate market entry in Europe Pinneberg, 5 February 2025 –Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) was informed by its majority shareholder (together with his wife) and CEO Uwe Perbandt about the off-market placement of a tot......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.02.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Erfolgreiche Umplatzierung von Aktien an strategischen Investor aus der Gesundheitsbranche zur gezielten Beschleunigung des Markteintritts in Europa
Article
News Preview
Viromed Medical AG: Erfolgreiche Umplatzierung von Aktien an strategischen Investor aus der Gesundheitsbranche zur gezielten Beschleunigung des Markteintritts in Europa Pinneberg, 5. Februar 2025 – Die Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) wurde von ihrem Mehrheitsaktionär (gemeinsam mit seiner Frau) und Vorstand Uwe Perbandt über ......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG completes acquisition of pharmedix GmbH
Article
News Preview
Viromed Medical AG completes acquisition of pharmedix GmbH Notarial purchase agreement signed today Consolidated revenues are expected to multiply to a low double-digit million euro amount in fiscal year 2025. Pinneberg, 20 December 2024 – Today, Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) completed the announced acquisition of pharmed......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG vollzieht Übernahme der pharmedix GmbH
Article
News Preview
Viromed Medical AG vollzieht Übernahme der pharmedix GmbH Notarieller Kaufvertrag heute unterzeichnet Für das Geschäftsjahr 2025 wird eine Vervielfachung des Konzernumsatzes auf einen niedrigen zweistelligen Millionen-Euro-Betrag erwartet Pinneberg, 20. Dezember 2024 – Die Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) hat heute durch not......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG seeks extensive cooperation with a major global Group
Article
News Preview
Viromed Medical AG seeks extensive cooperation with a major global Group Pinneberg, 11 December 2024 - Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; ‘Viromed’; the ‘Company’) is seeking an extensive cooperation with a major global Group that is also active in the pharmaceutical sector. Based on today's discussions, the subject of the coop......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG strebt umfangreiche Kooperation mit einem weltweit agierenden Großkonzern an
Article
News Preview
Viromed Medical AG strebt umfangreiche Kooperation mit einem weltweit agierenden Großkonzern an Pinneberg, 11. Dezember 2024 – Die Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; „Viromed“; die „Gesellschaft“) strebt eine umfangreiche Kooperation mit einem weltweit agierenden Großkonzern, der auch im Bereich Pharma geschäftlich aktiv ist, a......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Cooperation between relyon plasma GmbH and Viromed Medical GmbH
Article
News Preview
Viromed Medical AG: Cooperation between relyon plasma GmbH and Viromed Medical GmbH Pinneberg/Regensburg, 5 December 2024 –Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) is pleased to inform about the cooperation between its subsidiary Viromed Medical GmbH and relyon plasma GmbH, a subsidiary of TDK Electronics AG (link to the original news......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Kooperation zwischen relyon plasma GmbH und Viromed Medical GmbH
Article
News Preview
Viromed Medical AG: Kooperation zwischen relyon plasma GmbH und Viromed Medical GmbH Pinneberg/Regensburg, 5. Dezember 2024 – Die Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) informiert über die Kooperation ihrer Tochtergesellschaft Viromed Medical GmbH mit der relyon plasma GmbH, einer Tochtergesellschaft der TDK Electronics AG (Link zu......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG erweitert Vorstand – Christian Strauch als neues Vorstandsmitglied berufen
Article
News Preview
Viromed Medical AG erweitert Vorstand – Christian Strauch als neues Vorstandsmitglied berufen Pinneberg, 3. Dezember 2024 – Der Aufsichtsrat der Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; „Viromed“) hat mit Wirkung zum 1. Januar 2025 Herrn Christian Strauch als neues Mitglied in den Vorstand der Gesellschaft berufen. Der bisherige Allei......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board
Article
News Preview
Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board Pinneberg, 3 December 2024 – The Supervisory Board of Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) has appointed Mr. Christian Strauch as a new member of the company's Management Board with effect ......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2024
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG plans to acquire all shares in pharmedix GmbH by means of a capital increase against a contribution in kind, excluding subscription rights.
Article
News Preview
Viromed Medical AG plans to acquire all shares in pharmedix GmbH by means of a capital increase against a contribution in kind, excluding subscription rights. Pinneberg, 3 December 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) plans to acquire all shares in pharmedix GmbH, Hamburg, and thus to expand its po......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.